| Literature DB >> 30355372 |
Yi-Le Wu1, Xi-Yao Yang1, Meng-Shu Pan1, Ruo-Jie Li1, Xiao-Qian Hu1, Jing-Jing Zhang1, Li-Qi Yang1.
Abstract
Healthcare-associated infections (HAIs) are a major worldwide public-health problem, but less data are available on the long-term trends of HAIs and antimicrobial use in Eastern China. This study describes the prevalence and long-term trends of HAIs and antimicrobial use in a tertiary care teaching hospital in Hefei, Anhui, China from 2010 to 2017 based on annual point-prevalence surveys. A total of 12 505 inpatients were included; 600 HAIs were recorded in 533 patients, with an overall prevalence of 4.26% and a frequency of 4.80%. No evidence was found for an increasing or decreasing trend in prevalence of HAI over 8 years (trend χ2 = 2.15, P = 0.143). However, significant differences in prevalence of HAI were evident between the surveys (χ2 = 21.14, P < 0.001). The intensive care unit had the highest frequency of HAIs (24.36%) and respiratory tract infections accounted for 62.50% of all cases; Escherichia coli was the most common pathogen (16.67%). A 44.13% prevalence of antimicrobial use with a gradually decreasing trend over time was recorded. More attention should be paid to potential high-risk clinical departments and HAI types with further enhancement of rational antimicrobial use.Entities:
Year: 2018 PMID: 30355372 PMCID: PMC6518586 DOI: 10.1017/S0950268818002856
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 2.451
Prevalence and distribution of HAIs in a university hospital in Anhui, China, 2010–2017
| Variables | 2010–2011 ( | 2012–2013 ( | 2014–2015 ( | 2016–2017 ( | Total ( | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| % | % | % | % | % | ||||||
| Prevalence of patients with HAI | 109 | 5.03 | 96 | 3.03 | 133 | 4.02 | 195 | 5.04 | 533 | 4.26 |
| Frequency of HAIs | 117 | 5.40 | 104 | 3.28 | 161 | 4.87 | 218 | 5.64 | 600 | 4.80 |
| Relative proportion of infection sites | ||||||||||
| LRTIs | 46 | 39.32 | 37 | 35.57 | 65 | 40.37 | 93 | 42.66 | 241 | 40.17 |
| URTIs | 24 | 20.51 | 23 | 22.12 | 34 | 21.12 | 53 | 24.31 | 134 | 22.33 |
| GIs | 16 | 13.68 | 7 | 6.73 | 15 | 9.32 | 20 | 9.17 | 58 | 9.67 |
| UTIs | 9 | 7.69 | 9 | 8.65 | 11 | 6.83 | 9 | 4.13 | 38 | 6.33 |
| SSTIs | 6 | 5.13 | 4 | 3.85 | 7 | 4.35 | 17 | 7.80 | 34 | 5.67 |
| BSIs | 0 | 0.00 | 3 | 2.88 | 16 | 9.94 | 13 | 5.96 | 32 | 5.33 |
| SSIs | 9 | 7.69 | 6 | 5.77 | 3 | 1.86 | 2 | 0.92 | 20 | 3.33 |
| Others | 7 | 5.98 | 15 | 14.42 | 10 | 6.21 | 11 | 5.05 | 43 | 7.17 |
Distribution of HAIs in clinical wards in a university hospital in Anhui, China, 2010–2017
| Specialty of ward | 2010–2011 | 2012–2013 | 2014–2015 | 2016–2017 | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % | % | % | % | % | |||||||||||
| ICU | 15 | 3 | 20.00 | 47 | 12 | 25.53 | 39 | 10 | 25.64 | 55 | 13 | 23.64 | 156 | 38 | 24.36 |
| Haematology | 65 | 9 | 13.85 | 142 | 24 | 16.90 | 169 | 35 | 20.71 | 186 | 35 | 18.82 | 562 | 103 | 18.33 |
| Paediatrics and neonatology | 120 | 12 | 10.00 | 193 | 6 | 3.11 | 245 | 21 | 8.57 | 277 | 30 | 10.83 | 835 | 69 | 8.26 |
| Oncology | 286 | 25 | 8.74 | 444 | 10 | 2.25 | 488 | 25 | 5.12 | 497 | 45 | 9.05 | 1715 | 105 | 6.12 |
| Internal medicine | 685 | 31 | 4.53 | 1030 | 21 | 2.04 | 1034 | 42 | 4.06 | 1263 | 53 | 4.20 | 4012 | 147 | 3.66 |
| Surgery | 721 | 37 | 5.13 | 991 | 31 | 3.13 | 1011 | 21 | 2.08 | 1183 | 36 | 3.04 | 3906 | 125 | 3.20 |
| Gynaecology and obstetrics | 164 | 0 | 0.00 | 188 | 0 | 0.00 | 189 | 2 | 1.06 | 196 | 1 | 0.51 | 737 | 3 | 0.41 |
| Others | 110 | 0 | 0.0 | 131 | 0 | 0.00 | 132 | 5 | 3.79 | 209 | 5 | 2.39 | 582 | 10 | 1.72 |
Distribution of HAIs pathogens in a university hospital in Anhui, China, 2010–2017
| 2010–2011 | 2012–2013 | 2014–2015 | 2016–2017 | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| % | % | % | % | % | ||||||
| Gram-negative bacteria | 32 | 62.75 | 30 | 83.33 | 19 | 57.58 | 31 | 57.41 | 112 | 64.37 |
| 9 | 17.65 | 7 | 19.44 | 5 | 15.15 | 8 | 14.81 | 29 | 16.67 | |
| 6 | 11.76 | 7 | 19.44 | 4 | 12.12 | 5 | 9.26 | 22 | 12.64 | |
| 4 | 7.84 | 5 | 13.89 | 5 | 15.15 | 6 | 11.11 | 20 | 11.49 | |
| 3 | 5.88 | 2 | 5.56 | 1 | 3.03 | 5 | 9.26 | 11 | 6.32 | |
| 5 | 9.80 | 3 | 8.33 | 1 | 3.03 | – | – | 9 | 5.17 | |
| 2 | 3.92 | 3 | 8.33 | – | – | – | – | 5 | 2.87 | |
| 1 | 1.96 | – | – | – | – | – | – | 1 | 0.57 | |
| 1 | 1.96 | – | – | – | – | – | – | 1 | 0.57 | |
| 1 | 1.96 | – | – | – | – | – | – | 1 | 0.57 | |
| – | – | 1 | 2.78 | – | – | – | – | 1 | 0.57 | |
| – | – | 1 | 2.78 | – | – | – | – | 1 | 0.57 | |
| Other Gram-negative bacteria | – | – | 1 | 2.78 | 3 | 9.09 | 7 | 12.96 | 11 | 6.32 |
| Gram-positive bacteria | 9 | 17.65 | 3 | 8.33 | 9 | 27.27 | 11 | 20.37 | 32 | 18.39 |
| 3 | 5.88 | 1 | 2.78 | 4 | 12.12 | 5 | 9.26 | 13 | 7.47 | |
| 3 | 5.88 | 2 | 5.56 | 1 | 3.03 | 2 | 3.70 | 8 | 4.60 | |
| 3 | 5.88 | – | – | 1 | 3.03 | 1 | 1.85 | 5 | 2.87 | |
| – | – | – | – | 3 | 9.09 | 3 | 5.56 | 6 | 3.45 | |
| Fungus | 10 | 19.61 | 3 | 8.33 | 2 | 6.06 | 6 | 11.11 | 21 | 12.07 |
| 9 | 17.65 | 1 | 2.78 | 1 | 3.03 | – | – | 11 | 6.32 | |
| Other | 1 | 1.96 | 2 | 5.56 | 1 | 3.03 | – | – | 4 | 2.30 |
| Other fungi | – | – | – | – | – | – | 6 | 11.11 | 6 | 3.45 |
| Others | – | – | – | – | 3 | 9.09 | 6 | 11.11 | 9 | 5.17 |
| Total | 51 | 100.00 | 36 | 100.00 | 33 | 100.00 | 54 | 100.00 | 174 | 100.00 |
Antimicrobial use in a university hospital in Anhui, China, 2010–2017
| Variables | 2010–2011 ( | 2012–2013 ( | 2014–2015 ( | 2016–2017 ( | Total ( | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| % | % | % | % | % | ||||||
| Patients receiving antimicrobial agent | 1161 | 53.60 | 1439 | 45.45 | 1336 | 40.40 | 1583 | 40.95 | 5519 | 44.13 |
| Purpose of antimicrobial use | ||||||||||
| Treatment | 505 | 43.50 | 964 | 66.99 | 890 | 66.62 | 1012 | 63.93 | 3371 | 61.08 |
| Prophylaxis | 522 | 44.96 | 126 | 8.76 | 301 | 22.53 | 420 | 26.53 | 1369 | 24.81 |
| Treatment and Prophylaxis | 134 | 11.54 | 349 | 24.25 | 145 | 10.85 | 151 | 9.54 | 779 | 14.11 |
| Therapy | ||||||||||
| Mono therapy | 761 | 65.55 | 1196 | 83.11 | 967 | 72.38 | 1145 | 72.33 | 4069 | 73.73 |
| Dual therapy | 370 | 31.87 | 185 | 12.86 | 337 | 25.22 | 379 | 23.94 | 1271 | 23.03 |
| Triple (or multi-drug) therapy | 30 | 2.58 | 58 | 4.03 | 32 | 2.40 | 59 | 3.73 | 179 | 3.24 |